sharon sanders
Editor-in-Chief & President
bump this
-
FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website. -
We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.
Ivermectin - A useful treatment for COVID-19 coronavirus? Some discussion and studies...
- Thread starter Vibrant62
- Start date
tetano
Editor, Senior Moderator
Cureus . Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Cureus
. 2022 Jan 15;14(1):e21272.
doi: 10.7759/cureus.21272. eCollection 2022 Jan.
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Lucy Kerr[SUP] 1 [/SUP], Flavio A Cadegiani[SUP] 2 3 [/SUP], Fernando Baldi[SUP] 4 [/SUP], Raysildo B Lobo[SUP] 5 [/SUP], Washington Luiz O Assagra[SUP] 6 [/SUP], Fernando Carlos Proença[SUP] 7 [/SUP], Pierre Kory[SUP] 8 [/SUP], Jennifer A Hibberd[SUP] 9 [/SUP], Juan J Chamie-Quintero[SUP] 10 [/SUP]
Affiliations
Abstract
Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).
Results: Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
Keywords: coronavirus; covid-19; ivermectin; prevention; prophylaxis; sars-cov-2.
Cureus
. 2022 Jan 15;14(1):e21272.
doi: 10.7759/cureus.21272. eCollection 2022 Jan.
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Lucy Kerr[SUP] 1 [/SUP], Flavio A Cadegiani[SUP] 2 3 [/SUP], Fernando Baldi[SUP] 4 [/SUP], Raysildo B Lobo[SUP] 5 [/SUP], Washington Luiz O Assagra[SUP] 6 [/SUP], Fernando Carlos Proença[SUP] 7 [/SUP], Pierre Kory[SUP] 8 [/SUP], Jennifer A Hibberd[SUP] 9 [/SUP], Juan J Chamie-Quintero[SUP] 10 [/SUP]
Affiliations
- PMID: 35070575
- PMCID: PMC8765582
- DOI: 10.7759/cureus.21272
Abstract
Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).
Results: Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
Keywords: coronavirus; covid-19; ivermectin; prevention; prophylaxis; sars-cov-2.
sharon sanders
Editor-in-Chief & President
January 31, 20222:30 PM EST
Last Updated 15 hours ago
Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says
TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.
The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was "effective" against Omicron in Phase III clinical trials, which are conducted in humans.
Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy.
more...
https://www.reuters.com/business/he...e-against-omicron-phase-iii-trial-2022-01-31/
Last Updated 15 hours ago
Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says
TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.
The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was "effective" against Omicron in Phase III clinical trials, which are conducted in humans.
Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy.
more...
https://www.reuters.com/business/he...e-against-omicron-phase-iii-trial-2022-01-31/
sharon sanders
Editor-in-Chief & President
bump this
GardenSpider
Well-known member
Kowa Co. Ltd. & Kitasato University Pre-Clinical Lab Work: Ivermectin Inhibits Omicron & Other SARS-CoV-2 Variants of Concern
https://trialsitenews.com/kowa-co-l...omicron-other-sars-cov-2-variants-of-concern/
"Recently TrialSite reported that a Japanese pharmaceutical company, part of a large conglomerate known as Kowa Co. Ltd. Reported they were commencing a large 1000 patient Phase 3 clinical trial investigating the efficacy of ivermectin in COVID-19 patients with mild symptoms. With ambitious plans to end the study by the end of 2021 as reported in the Japanese press and apply for approval in early 2022, TrialSite questioned the feasibility of such an aggressive timeline. Yet now that same company has indicated to mainstream global media, including Reuters, that ivermectin showed an “antiviral effect” against Omicron and other SARS-CoV-2 variants in “joint non-clinical research” in partnership with Kitasato University, an academic medical center in Tokyo with a keen research interest in ivermectin as reported by TrialSite.....
IVERMECTIN SHOWED AN ANTIVIRAL EFFECT AGAINST OMICRON AND OTHER CORONAVIRUS VARIANTS IN JOINT NON-CLINICAL RESEARCH
"TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.....
https://www.reuters.com/business/he...e-against-omicron-phase-iii-trial-2022-01-31/
https://trialsitenews.com/kowa-co-l...omicron-other-sars-cov-2-variants-of-concern/
"Recently TrialSite reported that a Japanese pharmaceutical company, part of a large conglomerate known as Kowa Co. Ltd. Reported they were commencing a large 1000 patient Phase 3 clinical trial investigating the efficacy of ivermectin in COVID-19 patients with mild symptoms. With ambitious plans to end the study by the end of 2021 as reported in the Japanese press and apply for approval in early 2022, TrialSite questioned the feasibility of such an aggressive timeline. Yet now that same company has indicated to mainstream global media, including Reuters, that ivermectin showed an “antiviral effect” against Omicron and other SARS-CoV-2 variants in “joint non-clinical research” in partnership with Kitasato University, an academic medical center in Tokyo with a keen research interest in ivermectin as reported by TrialSite.....
IVERMECTIN SHOWED AN ANTIVIRAL EFFECT AGAINST OMICRON AND OTHER CORONAVIRUS VARIANTS IN JOINT NON-CLINICAL RESEARCH
"TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.....
https://www.reuters.com/business/he...e-against-omicron-phase-iii-trial-2022-01-31/
sharon sanders
Editor-in-Chief & President
bump this
sharon sanders
Editor-in-Chief & President
Another conflicting study. According to this study Ivermectin did not reduce hospitalization of COVID-19 positive patients.
N Engl J Med . Effect of Early Treatment with Ivermectin among Patients with Covid-19
N Engl J Med . Effect of Early Treatment with Ivermectin among Patients with Covid-19
Shiloh
Editor, Senior Moderator
Source: https://www.cureus.com/articles/111...ubjects?email_share=true&expedited_modal=true
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Lucy Kerr, Fernando Baldi, Raysildo Lobo, Washington Luiz Assagra, Fernando Carlos Proença, Juan J. Chamie, Jennifer A. Hibberd, Pierre Kory, Flavio A. Cadegiani
Published: August 31, 2022 (see history)
DOI: 10.7759/cureus.28624
Abstract
Background
We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect...
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Lucy Kerr, Fernando Baldi, Raysildo Lobo, Washington Luiz Assagra, Fernando Carlos Proença, Juan J. Chamie, Jennifer A. Hibberd, Pierre Kory, Flavio A. Cadegiani
Published: August 31, 2022 (see history)
DOI: 10.7759/cureus.28624
Abstract
Background
We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect...
Emily
Editor, Senior Moderator
I think this is a study on using it after exposure as a preventative.
https://www.uncoverdc.com/2023/02/1...ompany-proves-ivermectin-works-against-covid/
“Gold-Standard” RCT from Gates-Funded Company Proves Ivermectin Works Against COVID
By Michelle Edwards -
February 10, 2023
https://www.uncoverdc.com/2023/02/1...ompany-proves-ivermectin-works-against-covid/
“Gold-Standard” RCT from Gates-Funded Company Proves Ivermectin Works Against COVID
By Michelle Edwards -
February 10, 2023
Emily
Editor, Senior Moderator
https://johninengland.substack.com/...re-kory?utm_source=profile&utm_medium=reader2
My banned video with Dr. Pierre Kory
The full video on Substack
John Campbell
May 31, 2023
This one was first posted on 25[SUP]th[/SUP] April, 2021. It was banned about a week later because it mentioned the drug which dare not speak it’s name …. Ivermectin...
My banned video with Dr. Pierre Kory
The full video on Substack
John Campbell
May 31, 2023
This one was first posted on 25[SUP]th[/SUP] April, 2021. It was banned about a week later because it mentioned the drug which dare not speak it’s name …. Ivermectin...